A patient-derived colon cancer liver-metastasis cell line, CRC-X1, was stably passaged through 59 generations, formed tumors in 60% of mouse xenografts, and showed sensitivity to 5-fluorouracil but ...

Colorectal Cancer Trials to Watch at ESMO 2026 / cancer, cancer care, Cancer research, cancer treatment, chemotherapy, clinical trials, colorectal cancer, ...

Natera NTRA recently announced a strategic collaboration with TransCode Therapeutics to support enrollment in a Phase 2a trial evaluating TTX-MC138 in patients with colorectal cancer (CRC). Under the ...

A single preoperative blood sample may help improve the prediction of recurrence or metastasis in patients with colorectal ...

For decades, the standard of care for patients with resected stage II and III colon cancer has centred on surgery with consideration of postoperative adjuvant systemic therapy to reduce risk of ...

Agenus (NASDAQ:AGEN) is concentrating its registration strategy for BOT/BAL on the Phase III ROBBIN trial in neoadjuvant high-risk stage II and III microsatellite-stable (MSS) colon cancer, after ...

A single-patient case report documents bilateral ovarian metastases from colon cancer that ruptured 19 months after curative ...

KRAS G12D, INCA33890 and CDK2 combos show solid tumor promise ahead of Jakafi LOE—click for more on INCY stock.

The TASKIN trial found a 12-month overall survival rate of 61.3% with vilamakitug plus standard-of-care therapy, with ...

Phase 2 randomized, controlled study of pelareorep combined with 5-fluorouracil/leucovorin/ irinotecan (FOLFIRI) + bevacizumab (bev) for the second-line treatment of RAS-mutated, microsatellite-stable ...

(XBIT), a biotechnology company developing therapeutic antibodies, announced positive final efficacy results from the Phase 2 portion of the investigator-sponsored TASKIN trial evaluating vilamakitug ...

Investigator-sponsored study funded by the French National Cancer Institute (INCa) meets pre-specified primary efficacy ...